GlassScriptPhysician profile
Daniel Hartman Johnson
NPI 1841565173
$329,029.27
in general payments reported to CMS, 2019-2025
23 companies · $68K in 2025
The $68K reported for 2025 was more than what 96% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $7,645 · 2021: $37K · 2022: $53K · 2023: $87K · 2024: $77K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $207K · Travel and Lodging: $12K · Consulting Fee: $8,429 · Food and Beverage: $3,313 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $206,963.50 |
| Travel and Lodging | $12,208.96 |
| Consulting Fee | $8,429.00 |
| Food and Beverage | $3,312.54 |
| Education | $120.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $284,240.92 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $17,520.09 | 2021-2025 | Datroway, Imfinzi |
| Merck Sharp & Dohme LLC | $10,687.30 | 2019-2025 | Keytruda, Welireg |
| Array Biopharma INC | $6,080.00 | 2020-2021 | |
| Amgen INC. | $3,181.79 | 2022-2023 | |
| Pfizer INC. | $2,525.00 | 2020 | |
| Genzyme Corporation | $1,985.00 | 2021 | |
| Tempus Ai, INC | $1,395.66 | 2024 | Tempus Pixel |
| Daiichi Sankyo INC. | $820.48 | 2023-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $154.52 | 2021-2025 | Erleada, Balversa, Akeega |
| Beigene USA, INC. | $113.44 | 2023-2025 | Brukinsa |
| Beone Medicines USA, INC. | $57.66 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $49.16 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $43.77 | 2025 | Akeega, Erleada |
| Abbvie INC. | $36.02 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.99 | 2023 | Xtandi |
| Jazz Pharmaceuticals INC. | $21.01 | 2025 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Genentech USA, INC. | $20.80 | 2023 | Tecentriq, Alecensa |
| Seagen INC. | $19.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.89 | 2024 | |
| Novocure INC. | $14.54 | 2025 | Optune Lua (Novottf-200t) |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.